Follow-up of patients with mycosis fungoides after interferon α2b treatment failure

Ewa Chmielowska; Maciej Studziński; Sebastian Giebel; Anna Krause; Monika Olejniczak; Aleksandra Grzanka

doi:10.5114/pdia.2014.40941

Follow-up of patients with mycosis fungoides after interferon α2b treatment failure

Postepy Dermatol Alergol. 2015 Apr;32(2):67-72. doi: 10.5114/pdia.2014.40941. Epub 2015 Mar 30.

Authors

Ewa Chmielowska¹, Maciej Studziński², Sebastian Giebel³, Anna Krause¹, Monika Olejniczak¹, Aleksandra Grzanka⁴

Affiliations

¹ Clinical Oncology Department, Oncology Center, Bydgoszcz, Poland. Head of the Department: Ewa Chmielowska MD, PhD.
² Clinic of Oncology and Brachytherapy, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland. Head of the Department: Prof. Roman Makarewicz MD, PhD.
³ Department of Bone Marrow Transplantation and Hematooncology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland. Head of the Department: Prof. Sebastian Giebel.
⁴ Department of Dermatology, Univeristy Hosptal No. 1, Bydgoszcz, Poland. Head of the Department: Rafal Czajkowski MD, PhD.

Abstract

Introduction: Treatment of T cell cutaneous lymphoma( CTCL) is a controversial subject and the effectiveness of treatment is still low.

Aim: Report of single center experience of management CTCL after progression after first line treatment.

Material and methods: We present 41 patients with CTCL, 29 received interferon α2b in first line, and 12 of them received second line therapy.

Results: Overall response rate for second line therapy was 60%.

Conclusions: Results of the follow-up of patients with mycosis fungoides after interferon α2b treatment failure with the literature review and discussion.

Keywords: chemotherapy; interferon; mycosis fungoides.